Viewing nowCombinationSelmistar Tablet 40/5 mg
Telmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 201605776 · Approved 2016.09.30 · Insurance code 693902390
Treatment of essential hypertension not controlled with monotherapy
For patients with essential hypertension, blood pressure may not be sufficiently controlled by monotherapy with amlodipine or telmisartan alone. In such cases, additional treatment or combination therapy may help to manage blood pressure more effectively. This medication helps lower blood pressure and reduce the risk of cardiovascular complications. Consistent use and regular blood pressure monitoring are important, and lifestyle improvements should also be included. It assists in maintaining healthy vascular status through effective blood pressure control.
The recommended dose is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take the tablet at the same time each day (e.g., in the morning). It is recommended to adjust the dose using the individual components (amlodipine or telmisartan) before administering this medicine. However, if blood pressure is not controlled with the individual components as follows, switching directly to this medicine may be considered. - 40/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg. For patients taking telmisartan and amlodipine concomitantly, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience of administration (limited to this medicine 40/5 mg). ○ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to start treatment at a low dose and gradually increase the dose. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older adults: The usual amlodipine dosage regimen is recommended for older adults, but caution should be exercised when increasing the dose (see section ‘3. Patients requiring careful administration’). In older adults aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually.
○ Children: The safety and efficacy of this medicine have not been established in pediatric patients 18 years of age or younger; therefore, its use is not recommended.
This medication can pose serious risks to the fetus, especially during the second and third trimesters of pregnancy; therefore, it must be discontinued immediately if pregnancy is confirmed. This medication is contraindicated in patients with certain diseases or hypersensitivity to drugs, in pregnant or possibly pregnant women, nursing mothers, and patients with severely impaired liver or heart function. Additionally, patients with primary aldosteronism, specific heart valve diseases, liver impairment, gastrointestinal disorders, renal artery hypertension, patients on dialysis, and the elderly should use this medication cautiously. Those taking this drug may commonly experience side effects such as dizziness or peripheral edema, so caution is needed, and severe side effects may occur infrequently; if any unusual symptoms arise, it is important to consult medical personnel immediately. This medication lowers blood pressure, which can cause hypotension in patients with fluid or salt depletion; therefore, their status should be corrected, or dosage adjusted before administration. As there is a risk of increased potassium levels in the blood, patients at risk for hyperkalemia should have regular blood tests, and caution is particularly advised when using potassium supplements concurrently. Patients with impaired kidney function may experience further deterioration in kidney function while taking this medication; therefore, blood tests to monitor kidney function and electrolyte status should be conducted periodically. Patients with cardiovascular diseases may have an increased risk of angina or myocardial infarction when taking this medication, so careful observation of symptoms is required. This medication can cause drowsiness or dizziness, so caution should be exercised when driving or operating dangerous machinery. There may be interactions when this medication is used in combination with other antihypertensive agents, so it is essential to inform healthcare providers of any other medications being taken. Women who are pregnant or nursing should not use this medication, and those planning to become pregnant should consider alternative treatments. In pediatric patients, safety and efficacy have not been established adequately, so its use is not recommended. In case of overdose, symptoms like hypotension, dizziness, and cardiac arrhythmias may occur, requiring immediate medical attention. This medication should be kept out of reach of children and maintained in a sealed state until just prior to administration.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light, so it should be stored in a container that does not allow light to enter. Additionally, it is recommended to store it at room temperature between 1 degree and 30 degrees Celsius. This ensures the medication's effectiveness is maintained for a longer period.
This is a white and light gray, biconvex, oval-shaped double-coated tablet.
30 tablets (10 tablets/PTP X 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Vivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.